• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Magenta Therapeutics Inc. (Amendment)

    2/14/24 4:58:16 PM ET
    $MGTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MGTA alert in real time by email
    SC 13G/A 1 tm243953d13_sc13ga.htm SC 13G/A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G*

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2

    (Amendment No. 1)*

     

     

    Dianthus Therapeutics, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.001 per share (the “Shares”)
    (Title of Class of Securities)
     
    252828108
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event Which Requires Filing of the Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)
    x Rule 13d-1(c)
    o Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 252828108 13G Page 2 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel Advisors LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    355 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.0%1

    12.

    TYPE OF REPORTING PERSON

     

    IA; OO; HC

           

     

    _________________________

    1 The percentages reported in this Schedule 13G are based upon 14,817,696 Shares outstanding as of December 11, 2023 (according to the issuer’s Form S-1/A as filed with the Securities and Exchange Commission on December 21, 2023).

     

     

     

     

     

    CUSIP No. 252828108 13G Page 3 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel Advisors Holdings LP

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    355 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.0%

    12.

    TYPE OF REPORTING PERSON

     

    PN; HC

           

     

     

     

     

     

    CUSIP No. 252828108 13G Page 4 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel GP LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    355 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.0%

    12.

    TYPE OF REPORTING PERSON

     

    OO; HC

           

     

     

     

     

     

    CUSIP No. 252828108 13G Page 5 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel Securities LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    2,525 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.0%

    12.

    TYPE OF REPORTING PERSON

     

    BD; OO

           

     

     

     

     

     

    CUSIP No. 252828108 13G Page 6 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel Securities Group LP

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    2,525 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.0%

    12.

    TYPE OF REPORTING PERSON

     

    PN; HC

           

     

     

     

     

     

    CUSIP No. 252828108 13G Page 7 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel Securities GP LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    2,525 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.0%

    12.

    TYPE OF REPORTING PERSON

     

    OO; HC

           

     

     

     

     

     

    CUSIP No. 252828108 13G Page 8 of 13 Pages

     

     

    1.

    NAME OF REPORTING PERSONS

     

    Kenneth Griffin

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

     

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    U.S. Citizen

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    2,880 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.0%

    12.

    TYPE OF REPORTING PERSON

     

    IN; HC

           

     

     

     

     

     

    CUSIP No. 252828108 13G Page 9 of 13 Pages

     

     

    Item 1(a). Name of Issuer:
       
      Dianthus Therapeutics, Inc.
       
    Item 1(b). Address of Issuer’s Principal Executive Offices:
       
      7 Times Square, 43rd Floor, New York, NY 10036 United States 
       
    Item 2(a). Name of Person Filing:
       
      This Schedule 13G is being jointly filed by Citadel Advisors LLC (“Citadel Advisors”), Citadel Advisors Holdings LP (“CAH”), Citadel GP LLC (“CGP”), Citadel Securities LLC (“Citadel Securities”), Citadel Securities Group LP (“CALC4”), Citadel Securities GP LLC (“CSGP”) and Mr. Kenneth Griffin (collectively with Citadel Advisors, CAH, CGP, Citadel Securities, CALC4 and CSGP, the “Reporting Persons”) with respect to the Shares of the above-named issuer owned by Citadel Quantitative Strategies Master Fund Ltd., a Cayman Islands company (“QSMF”), and Citadel Securities.  Such owned Shares may include other instruments exercisable for or convertible into Shares.
       
      Citadel Advisors is the portfolio manager for QSMF. CAH is the sole member of Citadel Advisors. CGP is the general partner of CAH. CALC4 is the non-member manager of Citadel Securities.  CSGP is the general partner of CALC4.  Mr. Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP and CSGP.
       
      The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).
       
    Item 2(b). Address or Principal Business Office or, if none, Residence:
       
      The address of each of the Reporting Persons is Southeast Financial Center, 200 S. Biscayne Blvd., Suite 3300, Miami, Florida 33131.
       
    Item 2(c). Citizenship:
       
      Each of Citadel Advisors, CGP, Citadel Securities and CSGP is organized as a limited liability company under the laws of the State of Delaware.  Each of CALC4 and CAH is organized as a limited partnership under the laws of the State of Delaware.  Mr. Griffin is a U.S. citizen.
       
    Item 2(d). Title of Class of Securities:
       
      Common Stock, par value $0.001 per share
       
    Item 2(e). CUSIP Number:
       
      252828108

     

     

     

     

     

    CUSIP No. 252828108 13G Page 10 of 13 Pages

     

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
       
      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) ¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
      (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
      (g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
      (j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K).
             
      If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________.
             
    Item 4. Ownership:
             
      A. Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC
             
        (a) Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own 355 Shares.
             
        (b) The number of Shares that each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own constitutes 0.0% of the Shares outstanding.
             
        (c) Number of Shares as to which such person has:
             
          (i) sole power to vote or to direct the vote:  0
             
          (ii) shared power to vote or to direct the vote:  355
             
          (iii) sole power to dispose or to direct the disposition of:  0
             
          (iv) shared power to dispose or to direct the disposition of:  355

     

     

     

     

     

    CUSIP No. 252828108 13G Page 11 of 13 Pages

     

     

      B. Citadel Securities LLC
             
        (a) Citadel Securities LLC may be deemed to beneficially own 2,525 Shares.
           
        (b) The number of Shares that Citadel Securities LLC may be deemed to beneficially own constitutes 0.0% of the Shares outstanding.
           
        (c) Number of shares of Shares as to which such person has:
           
          (i) sole power to vote or to direct the vote:  0
             
          (ii) shared power to vote or to direct the vote:  2,525
             
          (iii) sole power to dispose or to direct the disposition of:  0
             
          (iv) shared power to dispose or to direct the disposition of:  2,525
             
      C. Citadel Securities Group LP and Citadel Securities GP LLC
             
        (a) Each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own 2,525 Shares.
           
        (b) The number of Shares that each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own constitutes 0.0% of the Shares outstanding.
           
        (c) Number of Shares as to which such person has:
           
          (i) sole power to vote or to direct the vote:  0
             
          (ii) shared power to vote or to direct the vote:  2,525
             
          (iii) sole power to dispose or to direct the disposition of:  0
             
          (iv) shared power to dispose or to direct the disposition of:  2,525
             

     

     

     

     

     

    CUSIP No. 252828108 13G Page 12 of 13 Pages

     

     

      D. Kenneth Griffin
             
        (a) Mr. Griffin may be deemed to beneficially own 2,880 Shares.
           
        (b) The number of Shares that Mr. Griffin may be deemed to beneficially own constitutes 0.0% of the Shares outstanding.
           
        (c) Number of Shares as to which such person has:
           
          (i) sole power to vote or to direct the vote:  0
             
          (ii) shared power to vote or to direct the vote:  2,880
             
          (iii) sole power to dispose or to direct the disposition of:  0
             
          (iv) shared power to dispose or to direct the disposition of:  2,880

     

    Item 5. Ownership of Five Percent or Less of a Class:
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following.   x
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person:
       
      Not Applicable
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
       
      Not Applicable
       
    Item 8. Identification and Classification of Members of the Group:
       
      Not Applicable
       
    Item 9. Notice of Dissolution of Group:
       
      Not Applicable
       
    Item 10. Certifications:
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

     

    CUSIP No. 252828108 13G Page 13 of 13 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Dated February 14, 2024.

     

    CITADEL SECURITIES LLC   CITADEL ADVISORS LLC  
               
    By: /s/ Guy Miller   By: /s/ Seth Levy  
      Guy Miller, Authorized Signatory     Seth Levy, Authorized Signatory  
               
               
    CITADEL SECURITIES GROUP LP   CITADEL ADVISORS HOLDINGS LP  
               
    By: /s/ Guy Miller   By: /s/ Seth Levy  
      Guy Miller, Authorized Signatory     Seth Levy, Authorized Signatory  
               
               
    CITADEL SECURITIES GP LLC   CITADEL GP LLC  
               
    By: /s/ Guy Miller   By: /s/ Seth Levy  
      Guy Miller, Authorized Signatory     Seth Levy, Authorized Signatory  
               
               
          KENNETH GRIFFIN  
               
          By: /s/ Seth Levy  
            Seth Levy, attorney-in-fact*  

     

     

    _________________________

    * Seth Levy is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein.  The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Allakos Inc. on October 13, 2023.

     

     

     

    Get the next $MGTA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MGTA

    DatePrice TargetRatingAnalyst
    8/25/2022$2.00Buy → Neutral
    Goldman
    1/24/2022$13.00 → $6.00Buy
    B. Riley Securities
    1/6/2022$7.00 → $8.00Neutral → Buy
    Goldman Sachs
    8/20/2021$7.00Neutral
    Goldman
    8/3/2021$16.00 → $7.00Overweight → Neutral
    JP Morgan
    7/22/2021$21.00 → $19.00Buy
    B. Riley Securities
    6/29/2021$20.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $MGTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Magenta Therapeutics Inc. (Amendment)

      SC 13G/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

      2/14/24 4:58:16 PM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Magenta Therapeutics Inc. (Amendment)

      SC 13G/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

      2/14/24 4:16:19 PM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Magenta Therapeutics Inc. (Amendment)

      SC 13G/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

      2/14/24 4:15:58 PM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MGTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Carr Edward

      4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

      1/26/24 4:51:02 PM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Veness Adam M

      4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

      1/26/24 4:46:18 PM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Randhawa Simrat

      4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

      1/26/24 4:43:38 PM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MGTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Magenta Therapeutics downgraded by Goldman with a new price target

      Goldman downgraded Magenta Therapeutics from Buy to Neutral and set a new price target of $2.00

      8/25/22 7:54:07 AM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B. Riley Securities reiterated coverage on Magenta Therapeutics with a new price target

      B. Riley Securities reiterated coverage of Magenta Therapeutics with a rating of Buy and set a new price target of $6.00 from $13.00 previously

      1/24/22 8:51:28 AM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Magenta Therapeutics upgraded by Goldman Sachs with a new price target

      Goldman Sachs upgraded Magenta Therapeutics from Neutral to Buy and set a new price target of $8.00 from $7.00 previously

      1/6/22 4:58:07 AM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MGTA
    SEC Filings

    See more
    • SEC Form S-1/A filed by Magenta Therapeutics Inc. (Amendment)

      S-1/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

      2/7/24 4:52:11 PM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Magenta Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

      1/22/24 7:34:29 AM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Magenta Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

      1/8/24 8:02:01 AM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MGTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Fairmount Funds Management Llc bought $336,252 worth of shares (24,670 units at $13.63) (SEC Form 4)

      4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

      10/3/23 4:00:40 PM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fairmount Funds Management Llc bought $394,500 worth of shares (30,000 units at $13.15) (SEC Form 4)

      4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

      9/28/23 5:09:20 PM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Randhawa Simrat bought $52,800 worth of shares (4,000 units at $13.20)

      4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

      9/25/23 4:15:07 PM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MGTA
    Leadership Updates

    Live Leadership Updates

    See more
    • Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors

      CAMBRIDGE, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that it has appointed Michael Vasconcelles, M.D. to its board of directors. Dr. Vasconcelles will also serve on the company's R&D Committee and Nominating and Corporate Governance Committee.  "We are delighted to welcome Mike Vasconcelles to the Magenta board," said Jason Gardner, D.Phil., President and Chief Executive Officer, Magenta Therapeutics. "Dr. Vasconcelles brings deep experience in research, medical operations, clinical trial design

      8/17/22 8:00:00 AM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Magenta Therapeutics Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer

      Magenta Therapeutics, Inc. (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced the appointment of Jeffrey Humphrey, M.D., as the company's Chief Medical Officer where he will be responsible for all clinical development and regulatory initiatives. Dr. Humphrey is a medical oncologist with significant leadership experience in drug development and has been involved with the development of more than 20 drug candidates, including regulatory submissions leading to multiple drug approvals in the United States and Europe. "As Magenta continues to advance our clinical and pr

      10/4/21 8:00:00 AM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Magenta Therapeutics Appoints Caren Deardorf as Chief Commercial Officer

      Magenta Therapeutics, Inc. (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced the appointment of Caren Deardorf as the company's first Chief Commercial Officer. "Caren has a highly sought-after balance of commercial success and hands-on experience, and we welcome her wide-ranging enterprise leadership expertise," said Jason Gardner, D.Phil., Chief Executive Officer and President, Magenta Therapeutics. "I look forward to working with her in establishing this new functionality as Magenta prepares to enter the next stage of pipeline and product candidate development." As Chief

      7/6/21 8:00:00 AM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MGTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Magenta Therapeutics Announces Completion of Merger with Dianthus Therapeutics and Implementation of Reverse Stock Split

      CAMBRIDGE, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics, Inc. (NASDAQ:MGTA) ("Magenta") today announced completion of the merger with Dianthus Therapeutics, Inc. ("Dianthus") following Magenta's successful receipt of stockholder approval for all proposals related to the merger at a special meeting of stockholders. Magenta effected a reverse stock split of Magenta's common stock immediately prior to the merger. Magenta following the merger is referred to herein as the "combined company." Steve Mahoney, President and Chief Financial and Operating Officer of Magenta said, "We are pleased with the outcome of the special meeting and appreciate our stockholders' support for th

      9/11/23 11:33:45 AM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement

      Merger to create Nasdaq-listed, clinical-stage biotechnology company focused on advancing Dianthus' portfolio of next-generation antibody complement therapeutics Combined company is expected to have approximately $180 million of cash or cash equivalents at close, including approximately $70 million from a concurrent private financing by Dianthus' new and existing investors, which is expected to provide funding into mid-2026 Cash expected to fund lead program DNTH103 through multiple clinical data catalysts including Phase 1 in healthy volunteers, and Phase 2 trials in generalized Myasthenia Gravis and other indications Companies will host a joint webcast today, May 3, 2023 at 8:30 a.m. ET

      5/3/23 7:00:00 AM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan

      CAMBRIDGE, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics, Inc. (NASDAQ:MGTA) ("Magenta" or the "Company") today announced that its Board of Directors (the "Board") has unanimously adopted a limited duration stockholder rights plan (the "Rights Plan"). The Rights Plan will give the Board sufficient time to conduct its previously announced comprehensive review of strategic alternatives focused on maximizing shareholder value. The Rights Plan has been adopted in order to protect the best interests of the Company and its shareholders, help ensure that all interested parties have the opportunity to participate fairly in the strategic review process, and provide the Board and sh

      3/31/23 4:10:00 PM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MGTA
    Financials

    Live finance-specific insights

    See more
    • Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan

      CAMBRIDGE, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics, Inc. (NASDAQ:MGTA) ("Magenta" or the "Company") today announced that its Board of Directors (the "Board") has unanimously adopted a limited duration stockholder rights plan (the "Rights Plan"). The Rights Plan will give the Board sufficient time to conduct its previously announced comprehensive review of strategic alternatives focused on maximizing shareholder value. The Rights Plan has been adopted in order to protect the best interests of the Company and its shareholders, help ensure that all interested parties have the opportunity to participate fairly in the strategic review process, and provide the Board and sh

      3/31/23 4:10:00 PM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Magenta Therapeutics Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates

      – MGTA-117 preliminary clinical results from 15 patients across three dose-escalation cohorts of the ongoing Phase 1/2 clinical trial shows single-agent activity with no dose-limiting toxicities; transition to patients with transplant-eligible AML/MDS expected in H1 2023 pending regulatory alignment – – CD45 antibody-drug conjugate (CD45-ADC) IND-enabling studies are advancing – – MGTA-145 clinical trial for stem cell mobilization in sickle cell disease patients is progressing with data now expected to be shared H1 2023 – – Conference call and webcast scheduled for 8:30am ET / 7:30am CT on December 13, 2022 – CAMBRIDGE, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (NAS

      12/12/22 4:30:00 PM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial

      CAMBRIDGE, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that it will host a conference call and webcast at 8:30 a.m. Eastern Time (ET) / 7:30 a.m. Central Time (CT) tomorrow, Tuesday, December 13, 2022 to review the MGTA-117 clinical data from its ongoing Phase 1/2 does escalation clinical trial that will be presented at the 2022 American Society of Hematology (ASH) Annual Meeting. The oral presentation at ASH, entitled "MGTA-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants

      12/12/22 8:00:00 AM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care